3-氧代-十二烷-(2-氨基环己酮) | 596104-55-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-氧代-十二烷-(2-氨基环己酮)
• 英文名称: N-(2-oxocyclohexyl)-3-oxododecamide
• 英文别名: 3-oxo-N-(2-oxocyclohexyl)dodecanamide
• CAS: 596104-55-1
• 化学式: C₁₈H₃₁NO₃
• 分子量: 309.449
• InChiKey: JDVHCWYKJODEND-UHFFFAOYSA-N

物化性质

• 沸点：
  496.7±45.0 °C(Predicted)
• 密度：
  1.01±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  63.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氧代月桂酸甲酯 在 sodium hydroxide 、 草酰氯 、 碳酸氢钠 、 对甲苯磺酸 、 N,N-二甲基甲酰胺 、 pyridinium chlorochromate 、 三氟乙酸 、 原甲酸三甲酯 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 133.5h， 生成 3-氧代-十二烷-(2-氨基环己酮)
  参考文献：
  名称：

  Synthesis and stability of small molecule probes for Pseudomonas aeruginosa quorum sensing modulation

  摘要：

  人类病原体铜绿假单胞菌（Pseudomonas aeruginosa）利用N-丁酰基-L-高丝氨酸内酯（BHL）和N-(3-氧代十二烷基)-L-高丝氨酸内酯（OdDHL）作为小分子细胞间信号，这种现象被称为群体感应（Quorum sensing，QS）。QS调节剂能有效减弱铜绿假单胞菌的毒力，因此，它们有可能成为一类新型抗菌剂。在生理条件下，BHL和OdDHL中的内酯环会发生水解，且水解速率快于α-手性中心的消旋化。设计并合成了非水解、非消旋的类似物（小分子探针），用酮基取代了内酯环。研究发现，除非在β-酮胺基之间进行二氟化，否则OdDHL类似物相对不稳定，易于分解。对一种非水解的环己酮类似物的稳定性研究显示，α-手性中心的消旋化相对较慢。该类似物的检测结果表明，L-异构体可能是铜绿假单胞菌和沙雷氏菌ATCC39006株中QS自诱导活性的原因。

  DOI：

  10.1039/b412802h

文献信息

• Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
  申请人：——

  公开号：US20040115732A1

  公开（公告）日：2004-06-17

  The present invention relates to solid phase or solution phase combinatorial libraries of autoinducer analogs. The present invention also relates to autoinducer agonists and antagonists. In addition, the present invention relates to methods for identifying autoinducer agonists and antagonists, as well as methods for regulating the activity of an autoinducer receptor, regulating biofilm formation, regulating growth or virulence of an organism in a subject, inhibiting the quorum sensing mechanism of an organism, and treating an infection in a subject caused by an organism possessing a quorum sensing mechanism which use the autoinducer analogs of the present invention.

  本发明涉及自感应剂类似物的固相或溶液相组合库。本发明还涉及自感应剂和拮抗剂。此外，本发明还涉及识别自感应剂和拮抗剂的方法，以及调节自感应受体的活性、调节生物膜形成、调节生物体在主体中的生长或毒力、抑制生物体的群体感应机制，并使用本发明的自感应剂类似物治疗由具有群体感应机制的生物体引起的主体感染。
• COMBINATORIAL LIBRARIES OF AUTOINDUCER ANALOGS, AUTOINDUCER AGONISTS AND ANTAGONISTS, AND METHODS OF USE THEREOF
  申请人：SUGA Hiroaki

  公开号：US20080027115A1

  公开（公告）日：2008-01-31

  The present invention relates to solid phase or solution phase combinatorial libraries of autoinducer analogs. The present invention also relates to autoinducer agonists and antagonists. In addition, the present invention relates to methods for identifying autoinducer agonists and antagonists, as well as methods for regulating the activity of an autoinducer receptor, regulating biofilm formation, regulating growth or virulence of an organism in a subject, inhibiting the quorum sensing mechanism of an organism, and treating an infection in a subject caused by an organism possessing a quorum sensing mechanism which use the autoinducer analogs of the present invention.

  本发明涉及自感应物类似物的固相或溶液相组合库。本发明还涉及自感应物激动剂和拮抗剂。此外，本发明还涉及识别自感应物激动剂和拮抗剂的方法，以及调节自感应物受体活性、调节生物膜形成、调节在受体中生物体的生长或毒力、抑制生物体的群体感应机制、以及使用本发明的自感应物类似物治疗由具有群体感应机制的生物体引起的受体感染的方法。
• Adherent oral pharmabiotic delivery strip
  申请人：Edwards Steven J.

  公开号：US11058634B2

  公开（公告）日：2021-07-13

  An oral pharmabiotic system is disclosed for improving oral, dental, and systemic health by repopulating and reshaping the flora within a patient's oral environment in a manner that overcomes the deficiencies of prior oral probiotic products. By formulating the pharmabiotic system as a strip for adhesive placement within a patients' oral cavity, preferably against the buccal mucosa, alveolar mucosa, oral labial mucosa, or a dental appliance, and configuring the parameters of the strip such that neither disadhesion nor complete dissolution occurs for at least a period of at least three hours during daytime use and at least six hours during nighttime use, the probiotic payload contained within may remain in the oral cavity for a sufficient length of time required for the probiotics to activate, replicate, and displace existing harmful oral pathobiotics.

  本发明公开了一种口服益生菌系统，通过重新填充和重塑患者口腔环境中的菌群，改善口腔、牙齿和全身健康，克服了以往口服益生菌产品的不足之处。将药用益生菌系统配制成条状，用于粘贴在患者口腔内，最好是粘贴在颊粘膜、牙槽粘膜、口腔唇粘膜或牙科器械上、并对条带的参数进行配置，使其在白天使用时至少三小时、夜间使用时至少六小时内既不会脱落，也不会完全溶解，从而使其中所含的益生菌有效载荷在口腔中保留足够长的时间，以便益生菌激活、复制和取代现有的有害口腔病原菌。
• Small molecule agents, compositions, and formulations, for internal use, displaying inhibitory activity against gram-positive and/or gram-negative organisms
  申请人：NATUREZA, INC.

  公开号：US11351134B2

  公开（公告）日：2022-06-07

  Active components comprising lauric acid, or a lauric acid derivative, are utilized independently, or in combination, to provide new and useful compositions for bacteriostatic action against susceptible pathogens. The lauric acid derivative includes one or more of 12-aminododecanoic acid, 12-amino-1-dodecanoic acid methyl ester, sucrose monolaurate, 12-(7-nitrobenzofurazan-4-ylamino) dodecanoic acid, 4-nitrophenyl dodecanoate, 1-lauroyl-rac-glycerol, 3-oxo-N-(2-oxocyclohexyl) dodecanamide, butyl laurate, benzyl laurate, isoamyl laurate, monolaurin, isopropyl laurate, pentyl laurate, and hexyl laurate. A preparation includes combining the active component with lecithin, and after an initial processing phase, coating with chitosan or a carrier. Final compositions may be or may contain particles, such as nanoparticles. Final compositions, or formulations containing said final compositions, may be utilized internally, causing one or more membrane changes (e.g., a membrane of an internal target pathogen, which may or may not be an antibiotic-resistant pathogen). At least some compositions inhibit growth of one or more Gram-positive bacterial species and one or more Gram-negative bacterial species.

  由月桂酸或月桂酸衍生物组成的活性成分可单独使用，也可组合使用，以提供对易感病原体具有抑菌作用的新型有用组合物。月桂酸衍生物包括 12-氨基十二烷酸、12-氨基-1-十二烷酸甲酯、蔗糖单月桂酸酯、12-（7-硝基苯并呋喃-4-基氨基）十二烷酸中的一种或多种、月桂酸丁酯、月桂酸苄酯、月桂酸异戊酯、月桂酸单月桂酯、月桂酸异丙酯、月桂酸戊酯和月桂酸己酯。制备方法包括将活性成分与卵磷脂结合，经过初始加工阶段后，涂上壳聚糖或载体。最终组合物可以是或可以包含颗粒，如纳米颗粒。最终组合物或含有所述最终组合物的制剂可在内部使用，引起一种或多种膜变化（例如，内部目标病原体的膜，可以是也可以不是抗生素抗性病原体）。至少有些组合物能抑制一种或多种革兰氏阳性细菌和一种或多种革兰氏阴性细菌的生长。
• INHIBITION OF MATURATION OF DENTAL BIOFILM AND CARIOGENIC PROPERTIES
  申请人：Koninklijke Philips N.V.

  公开号：EP3191089A1

  公开（公告）日：2017-07-19